Skip to main content
OpenTrials
Completed

NCT Number: NCT00828295

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

The objective of the study is to assess the safety and efficacy of two doses of IV palonosetron each administered as a single dose for the prevention of postoperative nausea and vomiting through 72 hours postoperatively in children aged 28 days up to 16 years inclusive undergoing surgical procedures requiring general endotracheal inhalation anesthesia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

28 day–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Federal State Institution Central Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov under the Federal Agency for High-Tech Medical Care, Moscow, Russia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

MAIN INCLUSION CRITERIA

  • Male or female patient aged more than 28 days (full term) up to and including 16 years.
  • Inpatient scheduled to undergo surgical procedures requiring general endotracheal anesthesia, including:
  • ear, nose and throat surgery;
  • eye surgery;
  • orchidopexy;
  • plastic reconstructive surgery;
  • herniorraphy;
  • orthopedic surgery).
  • American Society of Anesthesiologists (ASA) physical status I, II or III.
  • Patient scheduled to receive nitrous oxide during the maintenance phase of anesthesia.
  • Patient scheduled to be hospitalized for at least 72 hours after wake up of surgery
  • For female of childbearing potential: the patient and her parent(s)/legal guardian(s) were counseled on the importance of not becoming pregnant before or during the study and the patient must have a negative pregnancy test at the pre-treatment visit and at the study treatment visit.

MAIN EXCLUSION CRITERIA

  • For infant aged more than 12 months: a history of gastro-esophageal reflux.
  • For patient aged 28 days to 6 years: patient who received any investigational drugs within 90 days prior to Day 1. For patient aged 6 up to 16 years inclusive: patient who received any investigational drugs within 30 days prior to Day 1.
  • Patient scheduled to undergo emergency surgery.
  • Patient scheduled to receive regional (spinal) anesthesia in conjunction with general endotracheal anesthesia.
  • Patient scheduled to receive propofol during the maintenance phase of anesthesia.
  • Patient with vomiting from any organic cause.
  • Any drug with a potential anti-emetic effect within 24 hours prior to the administration of anesthesia.
  • Any vomiting, retching, or nausea in the 24 hours preceding the administration of anesthesia.

Treatment and study plan

Palonosetron

Drug

palonosetron IV 1 mcg/kg

Primary outcomes

  1. Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively

    Time frame: 0-72 hours post-operatively

Secondary outcomes

  1. Proportion of Patients With Complete Response 0-24 Hours

    Time frame: 0-24 hours

    Complete Response defined as no vomiting, no retching, and no use of rescue medication

Sponsors and collaborators

Lead sponsor

Helsinn Healthcare SA

Industry

Registry information

Official study title

A Multicenter, Double-blind, Randomized, Parallel Group, Stratified Study to Assess the Safety and Efficacy of Single IV Doses of Palonosetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Important dates

Study start
2008
Primary completion
2008
Study completion
2009
First posted
Jan 23, 2009
Registry last updated
Apr 3, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.